Effectiveness and Safety of Sacubitril/Valsartan in Patients with Chronic Kidney Disease—A Real-World Experience

Effectiveness and Safety of Sacubitril/Valsartan in Patients with Chronic Kidney Disease—A Real-World Experience

Background: data regarding the effectiveness and safety of sacubitril/valsartan in heart failure and reduced ejection fraction (HFrEF) patients with chronic kidney disease (CKD) are scarse. Objective: to evaluate the effectiveness and safety of sacubitril/valsartan in HFrEF and CKD in a real-world p...

Full description

Bibliographic Details
Main Authors:	Sara C. Pereira, Tiago Rodrigues, Afonso Nunes-Ferreira, João R. Agostinho, Fausto J. Pinto, Dulce Brito
Format:	Article
Language:	English
Published:	MDPI AG 2023-02-01
Series:	Journal of Clinical Medicine
Subjects:	chronic kidney disease glomerular filtration rate heart failure with reduced ejection fraction angiotensin receptor neprilysin inhibitor sacubitril/valsartan
Online Access:	https://www.mdpi.com/2077-0383/12/4/1334

Similar Items

The Efficacy and Safety of Sacubitril/Valsartan Compared to Valsartan in Patients with Heart Failure and Mildly Reduced and Preserved Ejection Fractions: A Systematic Review and Meta-Analysis of Randomized Controlled Trials
by: Sharath Kommu, et al.
Published: (2024-03-01)

Reverse remodelling by sacubitril/valsartan predicts the prognosis in heart failure with reduced ejection fraction
by: Mi‐Gil Moon, et al.
Published: (2021-06-01)

Sacubitril-Valsartan, Clinical Benefits and Related Mechanisms of Action in Heart Failure With Reduced Ejection Fraction. A Review
by: Domingo Pascual-Figal, et al.
Published: (2021-11-01)

The benefits of the earlier use of sacubitril/valsartan in de novo heart failure with reduced ejection fraction patients
by: Ji‐Hye Oh, et al.
Published: (2022-08-01)

Sacubitril/Valsartan in Heart Failure with Reduced Ejection Fraction: Real-World Experience from Italy (the REAL.IT Study)
by: Andrea Di Lenarda, et al.
Published: (2023-01-01)

Cardio-renal benefits of sacubitril/valsartan in patients with advanced chronic kidney disease: experience in daily clinical practice
by: María Dolores Martínez-Esteban, et al.
Published: (2022-08-01)

Clinical Effectiveness of Sacubitril/Valsartan Among Patients Hospitalized for Heart Failure With Reduced Ejection Fraction
by: Stephen J. Greene, et al.
Published: (2021-08-01)

Safety of sacubitril/valsartan initiated during hospitalization: data from a non‐selected cohort
by: Juan Carlos López‐Azor, et al.
Published: (2019-12-01)

Assessing clinical and biomarker characteristics to optimize the benefits of sacubitril/valsartan in heart failure
by: Sheldon E. Litwin, et al.
Published: (2022-12-01)

Effects of sacubitril-valsartan in patients undergoing maintenance dialysis
by: Ying Ding, et al.
Published: (2023-12-01)

Is Sacubitril/Valsartan Able to Change the Timing for Implantation of Cardiac Devices in Heart Failure with Reduced Ejection Fraction?
by: Marta Afonso Nogueira, et al.
Published: (2022-08-01)

A clinical experience of Indian patients with heart failure with reduced left ventricular ejection fraction using an angiotensin receptor-neprilysin inhibitor [ARNI] on an outpatient basis
by: Pankaj Jariwala, et al.
Published: (2021-03-01)

Haemodynamic forces predicting remodelling and outcome in patients with heart failure treated with sacubitril/valsartan
by: Iacopo Fabiani, et al.
Published: (2023-10-01)

Combined drug sacubitril/valsartan -a new era of treatment of chronic heart failure
by: V. S. Nikiforov
Published: (2020-10-01)

Molecular mechanisms of sacubitril/valsartan in cardiac remodeling
by: Nor Hidayah Mustafa, et al.
Published: (2022-08-01)

Is Sacubitril/Valsartan a Safe and Effective Option in Real World Patients with Mild to Severe Chronic Kidney Disease?
by: Marta Afonso Nogueira, et al.
Published: (2022-07-01)

The role of sacubitril/valsartan in the management of cardiac resynchronization therapy non‐responders: a retrospective analysis
by: Kyeong‐Hyeon Chun, et al.
Published: (2020-12-01)

Clinical outcomes of Sacubitril/Valsartan in patients with acute heart failure: A multi-institution study
by: Dong-Yi Chen, et al.
Published: (2021-11-01)

Sacubitril/Valsartan in Patients With Heart Failure and Concomitant End‐Stage Kidney Disease
by: Chih‐Yuan Niu, et al.
Published: (2022-09-01)

Reviewing the Modern Therapeutical Options and the Outcomes of Sacubitril/Valsartan in Heart Failure
by: Diana-Carina Iovanovici, et al.
Published: (2022-09-01)

Sacubitril-valsartan for the treatment of hypertension in China: A cost-utility analysis based on meta-analysis of randomized controlled trials
by: Yake Lou, et al.
Published: (2022-08-01)

Profile of sacubitril/valsartan in the treatment of heart failure: patient selection and perspectives
by: Yandrapalli S, et al.
Published: (2017-10-01)

Unlocking the potential of sacubitril/valsartan therapy in improving ECG and echocardiographic parameters in heart failure patients with reduced ejection fraction (HErEF)
by: Lamyaa Elsayed Allam, et al.
Published: (2024-03-01)

Safety and effectiveness of angiotensin receptor-neprilysin inhibitors in Indian patients with heart failure with preserved ejection fraction – “ARNI-PRESERVED” study
by: Pankaj Jariwala, et al.
Published: (2021-01-01)

Efficacy and safety of sacubitril/valsartan vs. valsartan in patients with acute myocardial infarction: A meta-analysis
by: Pei Yang, et al.
Published: (2022-08-01)

Evaluating the safety and tolerability of inpatient sacubitril/valsartan initiation in a community hospital
by: Katie L. Peppin, et al.
Published: (2020-01-01)

Pharmacoutilization and adherence to sacubitril/valsartan in real world: the REAL.IT study in HFrEF
by: Massimo Iacoviello, et al.
Published: (2024-02-01)

Influence of diabetes on sacubitril/valsartan titration and clinical outcomes in patients hospitalized for heart failure
by: Klaus K. Witte, et al.
Published: (2023-02-01)

Outcomes with sacubitril/valsartan in outpatients with heart failure and reduced ejection fraction: The ARIADNE registry
by: Aldo P. Maggioni, et al.
Published: (2022-12-01)

Initiation, treatment response evaluation, and safety monitoring of angiotensin receptor/neprilysin inhibitors (Sacubitril/Valsartan) in the management of heart failure in India: An expert group recommendations
by: Uday M Jadhav, et al.
Published: (2023-01-01)

Effects of Sacubitril/Valsartan on Serum Lipids in Heart Failure With Preserved Ejection Fraction
by: Senthil Selvaraj, et al.
Published: (2021-09-01)

Predictors of sacubitril/valsartan high dose tolerability in a real world population with HFrEF
by: Valeria Visco, et al.
Published: (2022-10-01)

First signs of reverse cardiac remodeling following one-month, low dose add-on sacubitril-valsartan therapy in patients with advanced systolic heart failure
by: Wioletta Sacharczuk, et al.
Published: (2022-03-01)

Sacubitril/valsartan attenuates atrial conduction disturbance and electrophysiological heterogeneity with ameliorating fibrosis in mice
by: Satoshi Iwamiya, et al.
Published: (2024-01-01)

Improved heart function and cardiac remodelling following sacubitril/valsartan in acute coronary syndrome with HF
by: Henan Liu, et al.
Published: (2024-04-01)

Effects of Sacubitril/Valsartan on the Right Ventricular Arterial Coupling in Patients with Heart Failure with Reduced Ejection Fraction
by: Daniele Masarone, et al.
Published: (2020-09-01)

Heart failure signs and symptoms, hospital referrals, and prescription patterns in patients receiving sacubitril/valsartan in primary care and cardiologist settings in Germany
by: Rolf Wachter, et al.
Published: (2020-10-01)

Safety and efficacy of ARNI (valsartan/sacubitril) vs ACEI (enalapril) in acute heart failure – A prospective observational study
by: Tahir Saleem Bhat, et al.
Published: (2022-05-01)

Effects of Sacubitril/Valsartan on biomarkers of fibrosis and inflammation in patients with heart failure with reduced ejection fraction
by: Giovanni Battista Bolla, et al.
Published: (2022-05-01)

EFFECTS OF SACUBITRIL/VALSARTAN ON THE ARTERIAL STIFFNESS AND LEFT VENTRICULAR-ARTERIAL COUPLING IN PATIENTS WITH HEART FAILURE WITH REDUCED EJECTION FRACTION
by: Zh. D. Kobalava, et al.
Published: (2018-05-01)